These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
416 related articles for article (PubMed ID: 37564196)
1. B7-H3 in Brain Malignancies: Immunology and Immunotherapy. Guo X; Chang M; Wang Y; Xing B; Ma W Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196 [TBL] [Abstract][Full Text] [Related]
2. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315 [TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy. Zhao B; Li H; Xia Y; Wang Y; Wang Y; Shi Y; Xing H; Qu T; Wang Y; Ma W J Hematol Oncol; 2022 Oct; 15(1):153. PubMed ID: 36284349 [TBL] [Abstract][Full Text] [Related]
4. B7-H3-targeted CAR-T cell therapy for solid tumors. Li G; Wang H; Wu H; Chen J Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615 [TBL] [Abstract][Full Text] [Related]
5. B7-H3/CD276: An Emerging Cancer Immunotherapy. Zhou WT; Jin WL Front Immunol; 2021; 12():701006. PubMed ID: 34349762 [TBL] [Abstract][Full Text] [Related]
6. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. Nehama D; Di Ianni N; Musio S; Du H; Patané M; Pollo B; Finocchiaro G; Park JJH; Dunn DE; Edwards DS; Damrauer JS; Hudson H; Floyd SR; Ferrone S; Savoldo B; Pellegatta S; Dotti G EBioMedicine; 2019 Sep; 47():33-43. PubMed ID: 31466914 [TBL] [Abstract][Full Text] [Related]
7. Targeting B7-H3-A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid Tumors Treatment. Rasic P; Jeremic M; Jeremic R; Dusanovic Pjevic M; Rasic M; Djuricic SM; Milickovic M; Vukadin M; Mijovic T; Savic D Molecules; 2023 Apr; 28(8):. PubMed ID: 37110590 [TBL] [Abstract][Full Text] [Related]
8. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. Theruvath J; Sotillo E; Mount CW; Graef CM; Delaidelli A; Heitzeneder S; Labanieh L; Dhingra S; Leruste A; Majzner RG; Xu P; Mueller S; Yecies DW; Finetti MA; Williamson D; Johann PD; Kool M; Pfister S; Hasselblatt M; Frühwald MC; Delattre O; Surdez D; Bourdeaut F; Puget S; Zaidi S; Mitra SS; Cheshier S; Sorensen PH; Monje M; Mackall CL Nat Med; 2020 May; 26(5):712-719. PubMed ID: 32341579 [TBL] [Abstract][Full Text] [Related]
9. B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma. Zhou Z; Luther N; Ibrahim GM; Hawkins C; Vibhakar R; Handler MH; Souweidane MM J Neurooncol; 2013 Feb; 111(3):257-64. PubMed ID: 23232807 [TBL] [Abstract][Full Text] [Related]
10. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824 [TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model. Tachi T; Kijima N; Kuroda H; Ikeda S; Murakami K; Nakagawa T; Yaga M; Nakagawa K; Utsugi R; Hirayama R; Okita Y; Kagawa N; Kishima H; Imai C; Hosen N Cancer Immunol Immunother; 2024 Oct; 73(12):256. PubMed ID: 39367952 [TBL] [Abstract][Full Text] [Related]
12. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy. Yang S; Wei W; Zhao Q Int J Biol Sci; 2020; 16(11):1767-1773. PubMed ID: 32398947 [TBL] [Abstract][Full Text] [Related]
13. In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment. Grote S; Ureña-Bailén G; Chan KC; Baden C; Mezger M; Handgretinger R; Schleicher S Cells; 2021 Apr; 10(5):. PubMed ID: 33925968 [TBL] [Abstract][Full Text] [Related]
14. CAR T cells redirected to B7-H3 for pediatric solid tumors: Current status and future perspectives. Epperly R; Gottschalk S; DeRenzo C EJC Paediatr Oncol; 2024 Jun; 3():. PubMed ID: 38957786 [TBL] [Abstract][Full Text] [Related]
15. B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer? Malapelle U; Parente P; Pepe F; Di Micco MC; Russo A; Clemente C; Graziano P; Rossi A Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555714 [TBL] [Abstract][Full Text] [Related]
16. Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety. Vitanza NA; Wilson AL; Huang W; Seidel K; Brown C; Gustafson JA; Yokoyama JK; Johnson AJ; Baxter BA; Koning RW; Reid AN; Meechan M; Biery MC; Myers C; Rawlings-Rhea SD; Albert CM; Browd SR; Hauptman JS; Lee A; Ojemann JG; Berens ME; Dun MD; Foster JB; Crotty EE; Leary SES; Cole BL; Perez FA; Wright JN; Orentas RJ; Chour T; Newell EW; Whiteaker JR; Zhao L; Paulovich AG; Pinto N; Gust J; Gardner RA; Jensen MC; Park JR Cancer Discov; 2023 Jan; 13(1):114-131. PubMed ID: 36259971 [TBL] [Abstract][Full Text] [Related]
17. Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models. Wang T; Zhang K; You F; Ma R; Yang N; Tian S; An G; Yang L Life Sci; 2023 Oct; 331():122024. PubMed ID: 37574043 [TBL] [Abstract][Full Text] [Related]
18. B7-H3: An Attractive Target for Antibody-based Immunotherapy. Kontos F; Michelakos T; Kurokawa T; Sadagopan A; Schwab JH; Ferrone CR; Ferrone S Clin Cancer Res; 2021 Mar; 27(5):1227-1235. PubMed ID: 33051306 [TBL] [Abstract][Full Text] [Related]
19. Identification of genetic modifiers enhancing B7-H3-targeting CAR T cell therapy against glioblastoma through large-scale CRISPRi screening. Li X; Sun S; Zhang W; Liang Z; Fang Y; Sun T; Wan Y; Ma X; Zhang S; Xu Y; Tian R J Exp Clin Cancer Res; 2024 Apr; 43(1):95. PubMed ID: 38561797 [TBL] [Abstract][Full Text] [Related]
20. Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia. Lichtman EI; Du H; Shou P; Song F; Suzuki K; Ahn S; Li G; Ferrone S; Su L; Savoldo B; Dotti G Clin Cancer Res; 2021 Jun; 27(11):3141-3153. PubMed ID: 33531429 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]